Kamada Licenses Alvotech Biosimilars In Israel

First Launch, Teriparatide, Is Slated For 2022

 
• By David Wallace
  
Israel
Kamada’s deal gives it rights to Alvotech’s Portfolio In Israel • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business